Home / Insights / What is MLR review? The process, and where AI actually helps
Guide

What is MLR review? The process, and where AI actually helps

Summarize with AI Prompt copied — paste it into the chat

MLR review stands for Medical, Legal and Regulatory review — the formal process by which a pharmaceutical or biotech company vets promotional and scientific content before it reaches a healthcare professional or a patient. Nothing goes out without it, and in most organisations a cycle runs in weeks rather than days.

What the three letters actually check

Each reviewer is looking for a different failure, which is why the process is cross-functional rather than sequential sign-off by one person.

  • Medical. Is every claim supported by the referenced data, is the science represented fairly, and is the balance between benefit and risk accurate?
  • Legal. Does the material create liability — comparative claims, off-label implication, intellectual property, contractual exposure?
  • Regulatory. Does it comply with the approved label and the applicable codes and regulator expectations in each market it will appear in?

A piece can pass two and fail the third, which is the usual reason for a second and third cycle.

Why it takes weeks

Rarely because reviewers are slow. The time goes into four places that have nothing to do with reading.

  • Queueing. Reviewers are senior people with other jobs. Material waits.
  • Round trips. A comment on slide four triggers a change on slide eleven, and the whole asset re-enters review.
  • Reference checking. Verifying that each claim maps to the cited source is mechanical, slow and where most of the corrections land.
  • Version confusion. Which draft is under review, and which comments belong to which version — very often tracked in a spreadsheet.

Only the first of those is a capacity problem. The other three are handling problems, which is precisely why AI has an opening here.

Where AI genuinely helps

Veeva reports up to a 75% reduction in MLR cycle time with AI-supported review, and Falcon MLR — its agentic compliance layer built on the Copli acquisition and integrated with PromoMats and Veeva MedComms — targets a 70% reduction in manual MLR labour over five years. See Veeva’s own material on AI-supported MLR.

The useful reading of those numbers is which tasks they come from:

  • Pre-review checks. Catching the obvious failures before a reviewer ever opens the file, so cycles are spent on judgement instead of on formatting and missing references.
  • Reference verification. Matching each claim to its cited source. Mechanical, exhaustive, and unpleasant for a human to do at volume.
  • Content reuse. Recognising that a claim has already been approved elsewhere and does not need re-litigating.
  • Queue and version state. Knowing what is where — the part still living in a spreadsheet in most organisations, where roughly 88% of spreadsheets contain errors.

The caveat that matters

Every published figure assumes the operating model changes too. Vendors building around content reuse, pre-review checks and tiered workflows report large cycle-time cuts precisely because the workflow was redesigned, not because a model was added to it.

AI applied to an unchanged review process mostly makes the existing bottleneck arrive sooner. If reviewers are the constraint and material simply reaches them faster, you have built a faster queue.

Where to start, if you are not on a platform

Not every organisation running MLR has Veeva. If you do not, the first move is not to buy a platform — it is to fix the thing that decides whether anything is on time.

Start with queue and version state: what is in review, with whom, since when, against which version. That is process metadata, so no unpublished scientific content leaves your environment — which matters, because Wiley, Wolters Kluwer and Elsevier all warn against putting unpublished material into general-purpose LLMs. It is the cheapest, lowest-risk and most visible starting point, and it builds the audit trail you will want before anything touches content.

We have set out the wider picture in AI for medical publishing and compared the tooling by job — including PromoMats, Quick Check and Falcon MLR — in AI tools for medical publishing.

Want to know where you stand under the AI Act?

Our AI Act Check (€950 fixed) gives you your risk classification, obligations and a concrete to-do list within one week — including what you can safely ignore.

See the AI Act Check →

Frequently asked questions

What does MLR review stand for?

Medical, Legal and Regulatory review — the cross-functional process by which a pharmaceutical or biotech company vets promotional and scientific content before it reaches healthcare professionals or patients. Medical checks whether claims are supported by data, Legal checks liability exposure, and Regulatory checks compliance with the approved label and applicable codes.

What is the MLR review process in pharma?

Content is submitted for simultaneous review by medical, legal and regulatory reviewers, each looking for a different kind of failure. Comments come back, the asset is revised, and it re-enters review. Cycles routinely run weeks, mostly because of queueing for senior reviewers, round trips triggered by one change, manual reference checking and version confusion.

How much can AI speed up MLR review?

Veeva reports up to 75% cycle-time reduction with AI-supported review, and Falcon MLR targets 70% less manual MLR labour over five years. Those figures assume the operating model changes as well — pre-review checks, content reuse and tiered workflows. AI applied to an unchanged process mostly makes the existing bottleneck arrive sooner.

Why does MLR review take so long?

Four reasons, and only one is capacity. Reviewers are senior people with other responsibilities, so material queues. A single comment can trigger changes elsewhere and send the whole asset back round. Reference checking against cited sources is manual and slow. And version state — which draft is under review with which comments — is usually tracked in a spreadsheet.

Where should we start with AI in MLR if we do not use Veeva?

With queue and version state rather than with content. Knowing what is in review, with whom, since when and against which version is process metadata, so no unpublished scientific content leaves your environment — which matters, because major publishers warn against putting unpublished material into general-purpose LLMs. It is the cheapest and lowest-risk start, and it builds the audit trail you want before anything touches content.
Our AI services Hire an AI consultant AI automation AI agents AI implementation Pricing

Want any of this applied to your business?

We turn these concepts into working tools — grounded, safe and measurable. Start with a free consultation.

Book a free consultation →